Iradimed Earnings Estimate

IRMD Stock  USD 99.94  0.13  0.13%   
The next projected EPS of Iradimed is estimated to be 0.45 with future projections ranging from a low of 0.44 to a high of 0.45. Iradimed's most recent 12-month trailing earnings per share (EPS TTM) is at 1.75. Please be aware that the consensus of earnings estimates for Iradimed Co is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
 
Interest Hikes
Iradimed is projected to generate 0.45 in earnings per share on the 31st of March 2026. Iradimed earnings estimates show analyst consensus about projected Iradimed Co EPS (Earning Per Share). It derives the highest and the lowest estimates based on Iradimed's historical volatility. Many public companies, such as Iradimed, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Iradimed's earnings estimates, investors can diagnose different trends across Iradimed's analyst sentiment over time as well as compare current estimates against different timeframes. As of February 16, 2026, Gross Profit is expected to decline to about 32.7 M. In addition to that, Pretax Profit Margin is expected to decline to 0.19Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Iradimed Earnings Estimation Breakdown

The calculation of Iradimed's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Iradimed is estimated to be 0.45 with the future projection ranging from a low of 0.44 to a high of 0.45. Please be aware that this consensus of annual earnings estimates for Iradimed Co is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.54
0.44
Lowest
Expected EPS
0.45
0.45
Highest

Iradimed Earnings Projection Consensus

Suppose the current estimates of Iradimed's value are higher than the current market price of the Iradimed stock. In this case, investors may conclude that Iradimed is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Iradimed's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2026Current EPS (TTM)
292.01%
0.54
0.45
1.75

Iradimed Earnings History

Earnings estimate consensus by Iradimed analysts from Wall Street is used by the market to judge Iradimed's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we suggest analyzing not only Iradimed's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Iradimed Quarterly Gross Profit

17.03 Million

At present, Iradimed's Earnings Yield is projected to increase slightly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 85.36, whereas Retained Earnings Total Equity is forecasted to decline to about 30.9 M. The current year's Common Stock Shares Outstanding is expected to grow to about 13.2 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 15.5 M.
Hype
Prediction
LowEstimatedHigh
98.0299.84101.66
Details
Intrinsic
Valuation
LowRealHigh
89.83115.16116.98
Details
2 Analysts
Consensus
LowTargetHigh
109.20120.00133.20
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Iradimed assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Iradimed. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Iradimed's stock price in the short term.

Iradimed Earnings per Share Projection vs Actual

Actual Earning per Share of Iradimed refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Iradimed Co predict the company's earnings will be in the future. The higher the earnings per share of Iradimed, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Iradimed Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Iradimed, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Iradimed should always be considered in relation to other companies to make a more educated investment decision.

Iradimed Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Iradimed's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2026-02-11
2025-12-310.4650.540.07516 
2025-10-30
2025-09-300.460.470.01
2025-08-01
2025-06-300.440.490.0511 
2025-05-05
2025-03-310.380.37-0.01
2025-02-13
2024-12-310.410.4-0.01
2024-10-31
2024-09-300.390.430.0410 
2024-08-01
2024-06-300.370.420.0513 
2024-05-02
2024-03-310.340.360.02
2024-02-08
2023-12-310.40.39-0.01
2023-11-03
2023-09-300.360.430.0719 
2023-08-03
2023-06-300.310.360.0516 
2023-05-04
2023-03-310.280.30.02
2023-02-02
2022-12-310.30.320.02
2022-11-03
2022-09-300.250.290.0416 
2022-07-29
2022-06-300.240.260.02
2022-04-29
2022-03-310.210.220.01
2022-02-04
2021-12-310.210.330.1257 
2021-10-29
2021-09-300.170.230.0635 
2021-07-30
2021-06-300.10.140.0440 
2021-04-30
2021-03-310.10.130.0330 
2021-02-04
2020-12-310.110.07-0.0436 
2020-10-30
2020-09-300.10.110.0110 
2020-07-30
2020-06-30-0.010.050.06600 
2020-04-30
2020-03-310.150.180.0320 
2020-02-06
2019-12-310.210.30.0942 
2019-10-30
2019-09-300.160.230.0743 
2019-07-30
2019-06-300.150.20.0533 
2019-04-30
2019-03-310.150.13-0.0213 
2019-02-06
2018-12-310.130.160.0323 
2018-10-30
2018-09-300.10.140.0440 
2018-07-31
2018-06-300.10.140.0440 
2018-04-30
2018-03-310.060.10.0466 
2018-02-06
2017-12-310.060.10.0466 
2017-10-30
2017-09-300.030.070.04133 
2017-07-28
2017-06-300.010.060.05500 
2017-04-28
2017-03-310.01-0.02-0.03300 
2017-02-06
2016-12-310.040.110.07175 
2016-10-28
2016-09-300.110.140.0327 
2016-07-29
2016-06-300.210.240.0314 
2016-04-29
2016-03-310.180.210.0316 
2016-02-05
2015-12-310.190.220.0315 
2015-10-30
2015-09-300.160.190.0318 
2015-07-30
2015-06-300.120.160.0433 
2015-04-30
2015-03-310.120.140.0216 
2015-02-05
2014-12-31-0.010.030.04400 
2014-10-30
2014-09-30-0.010.030.04400 

About Iradimed Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Iradimed earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Iradimed estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Iradimed fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings65.3 M68.6 M
Retained Earnings Total Equity54.4 M30.9 M
Earnings Yield 0.02  0.02 
Price Earnings Ratio 55.05  85.36 
Price Earnings To Growth Ratio 3.35  3.51 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Health Care Equipment & Supplies sector continue expanding? Could Iradimed diversify its offerings? Factors like these will boost the valuation of Iradimed. Market participants price Iradimed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iradimed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
0.247
Dividend Share
0.71
Earnings Share
1.75
Revenue Per Share
6.588
Quarterly Revenue Growth
0.17
Iradimed's market price often diverges from its book value, the accounting figure shown on Iradimed's balance sheet. Smart investors calculate Iradimed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Iradimed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.